Dian Diagnostics GroupLtd Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Haibin Chen

Chief executive officer

CN¥6.3m

Total compensation

CEO salary percentage	n/a
CEO tenure	14yrs
CEO ownership	26.5%
Management average tenure	4.2yrs
Board average tenure	2.1yrs

Recent management updates

Recent updates

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Apr 30

Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Apr 22

CEO

Haibin Chen (54 yo)

14yrs

Tenure

CN¥6,310,400

Compensation

Mr. Haibin Chen,B.S. (EMBA) serves as Chairman of the Board at Dian Diagnostics Group Co. Ltd and serves as its Chief Executive Officer since November 2023. He was the Chairman, General Manager and Preside...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Haibin Chen	GM & Chairman of the Board	14yrs	CN¥6.31m	26.55% CN¥ 2.3b
Sanhui Guo	Deputy General Manager & Director	5.3yrs	CN¥5.46m	0.015% CN¥ 1.3m
Jun Tao	Deputy GM & Secretary of the Board	3yrs	CN¥2.44m	no data
Hanhua Hong	Deputy General Manager & Director	less than a year	no data	no data

4.2yrs

Average Tenure

51yo

Average Age

Experienced Management: 300244's management team is considered experienced (4.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Haibin Chen	GM & Chairman of the Board	14yrs	CN¥6.31m	26.55% CN¥ 2.3b
Sanhui Guo	Deputy General Manager & Director	4.7yrs	CN¥5.46m	0.015% CN¥ 1.3m
Hanhua Hong	Deputy General Manager & Director	less than a year	no data	no data
Xiuli Cheng	Chairman of Supervisory Board	no data	CN¥340.00k	no data
Shishi Chen	Employees Representative Member of the Supervisory Board	no data	CN¥280.00k	no data
Weiru Chen	Independent Director	6.8yrs	CN¥120.00k	no data
Ding Guoqi	Independent Director	6.8yrs	CN¥120.00k	no data
Xiaoping Ye	Non-Independent Director	less than a year	no data	no data
Tiantian Li	Independent Director	3.7yrs	CN¥120.00k	no data
Dechao Yu	Non-Independent Director	less than a year	no data	no data
Bin Jiang	Independent Director	less than a year	no data	no data
Zelin Deng	Independent Director	less than a year	no data	no data

2.1yrs

Average Tenure

52yo

Average Age

Experienced Board: 300244's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Dian Diagnostics GroupLtd Management

Management criteria checks 2/4

Key information

Recent management updates

Dian Diagnostics Group Co.,Ltd., Annual General Meeting, May 20, 2024

Dian Diagnostics Group Co.,Ltd. Announces Executive Appointments

Less than half of directors are independent

Less than half of directors are independent

Dian Diagnostics Group Co.,Ltd. Announces Board Elations

Recent updates

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Dian Diagnostics Group Co.,Ltd., Annual General Meeting, May 20, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.3% to CN¥28.27

Dian Diagnostics Group Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Dian Diagnostics Group Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Dian Diagnostics Group Co.,Ltd. Announces Executive Appointments

Price target decreased by 9.9% to CN¥31.56

Third quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 20%

Price target decreased by 8.0% to CN¥37.35

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend for A Shares, Payable on 31 May 2023

Dian Diagnostics Group Co.,Ltd. Approves Cash Dividend for 2022

Price target decreased by 10% to CN¥38.72

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 10%, revenue upgraded

Consensus EPS estimates fall by 43%

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) announces an Equity Buyback for CNY 50 million worth of its shares.

Less than half of directors are independent

Consensus revenue estimates increase by 14%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 14%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 08 June 2022

Less than half of directors are independent

Dian Diagnostics Group Co.,Ltd. Announces Dividend for 2021

Now 20% undervalued

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dian Diagnostics Group Co.,Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued after recent price drop

Now 23% undervalued after recent price drop

Price target decreased to CN¥48.50

Third quarter 2021 earnings released: EPS CN¥0.81 (vs CN¥0.64 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.63 (vs CN¥0.80 in 2Q 2020)

Investor sentiment improved over the past week

Price target decreased to CN¥52.85

Dian Diagnostics Group Co.,Ltd. Approved Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.55 (vs CN¥0.011 in 1Q 2020)

Consensus EPS estimates increase to CN¥1.82

Full year 2020 earnings released: EPS CN¥1.29 (vs CN¥0.56 in FY 2019)

New 90-day low: CN¥32.92

Dian Diagnostics Group Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 10, 2021

Investor sentiment deteriorated over the past week

New 90-day high: CN¥43.96

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target raised to CN¥53.63

New 90-day low: CN¥36.20

Analysts update estimates

Third quarter earnings released

Dian Diagnostics Group Co.,Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Dian Diagnostics Group Co.,Ltd. Announces Board Elations

Hu Yong and Xu Min completed the acquisition of 10% stake in Zhejiang Di’an Diagnostic Technology Co., Ltd. from Chen Haibin and Lai Cuiying.

Analysts update estimates

Earnings released

Price target raised to CN¥35.41

New 90-day high - CN¥40.49

Dian Diagnostics Group Co.,Ltd. to Report First Half, 2020 Results on Aug 19, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age